Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug development

Anti-cholesterol vaccine shows promise

A vaccine that targets PCSK9 could be a cost effective approach to lowering cholesterol.

Researchers report on a vaccine that targets PCSK9 (molecular structure pictured), a protein that mediates the degradation of circulating LDL-C. Researchers say that a vaccine approach could be more cost-effective and practical

Source: Shutterstock.com

The PCSK9 protein (pictured) mediates the degradation of circulating low-density lipoprotein cholesterol

Statins, which reduce low-density lipoprotein cholesterol (LDL-C), are the standard of care for patients with raised cholesterol. However, they can cause side effects and are not always effective.

US researchers report on a vaccine that targets PCSK9, a protein that mediates the degradation of circulating LDL-C. People who lack functioning PCSK9 have reduced LDL-C levels and a much lower rate of cardiovascular disease.

Mice and macaques who received the vaccine developed antibodies against PCSK9 and had reduced circulating levels of the protein. Vaccination was associated with significant reductions in cholesterol, phospholipids and triglycerides and, in macaques, was shown to act synergistically with statin treatment to reduce LDL-C.

The researchers, writing in Vaccine[1] (2015;33:5747–5755), say that although there are monoclonal antibody therapies that target PCSK9, a vaccine approach could be more cost effective and practical.

Citation: Clinical Pharmacist DOI: 10.1211/PJ.2015.20200112

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Researchers report on a vaccine that targets PCSK9 (molecular structure pictured), a protein that mediates the degradation of circulating LDL-C. Researchers say that a vaccine approach could be more cost-effective and practical

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.